You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

obinutuzumab

Showing 1 - 25 of 229
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Idiopathic Membranous Nephropathy

Not yet recruiting
  • Idiopathic Membranous Nephropathy
  • Obinutuzumab Injection
  • (no location specified)
May 8, 2023

Follicular Lymphoma, Tumor Trial in Houston (Obinutuzumab, CC-99282)

Not yet recruiting
  • Follicular Lymphoma
  • Tumor
  • Houston, Texas
    M D Anderson Cancer Center
Oct 30, 2023

CLL Trial (Sonrotoclax, Zanubrutinib, Venetoclax)

Not yet recruiting
  • CLL
  • (no location specified)
Oct 3, 2023

Large B-cell Lymphoma Trial (Glofitamab, Polatuzumab vedotin, Obinutuzumab)

Not yet recruiting
  • Large B-cell Lymphoma
  • (no location specified)
Oct 3, 2023

Chronic Lymphocytic Leukemia Trial (Acalabrutinib, Obinutuzumab)

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • (no location specified)
Jul 10, 2023

Immune Thrombocytopenia, Treatment Trial in Tianjin (Obinutuzumab Injection [Gazyva])

Not yet recruiting
  • Immune Thrombocytopenia
  • Treatment
  • Obinutuzumab Injection [Gazyva]
  • Tianjin, China
    Institute of Hematology and Blood Diseases Hospital, Chinese Aca
Oct 17, 2023

Immune Thrombocytopenia, Treatment Trial in Tianjin (Obinutuzumab Injection [Gazyva])

Not yet recruiting
  • Immune Thrombocytopenia
  • Treatment
  • Obinutuzumab Injection [Gazyva]
  • Tianjin, China
    Chinese Academy of Medical Science and Blood Disease Hospital
Aug 9, 2023

Obinutuzumab-based Therapy for Previously Untreated FL

Recruiting
  • Follicular Lymphoma
  • Obinutuzumab
  • +6 more
  • Shanghai, Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
Jun 3, 2023

Urothelial Carcinoma Trial in New York (Naptumomab Estafenatox, Pembrolizumab, Obinutuzumab)

Not yet recruiting
  • Urothelial Carcinoma
  • Naptumomab Estafenatox
  • +2 more
  • New York, New York
    Weill Cornell Medicine/NewYork-Presbyterian Hospital
May 30, 2023

Steroid-Dependent Nephrotic Syndrome, Steroid-Sensitive Nephrotic Syndrome Trial in Paris (single infusion of Rituximab, single

Not yet recruiting
  • Steroid-Dependent Nephrotic Syndrome
  • Steroid-Sensitive Nephrotic Syndrome
  • single infusion of Rituximab
  • single infusion of Obinutuzumab
  • Paris, France
    Robert Debre Hospital
Mar 14, 2023

Marginal Zone Lymphoma Trial in Tianjin (Obinutuzumab, lenalidomide)

Recruiting
  • Marginal Zone Lymphoma
  • Obinutuzumab, lenalidomide
  • Tianjin, Tian, China
    Institute of Hematology & Blood Diseases Hospital
Apr 27, 2023

Acute Lymphoblastic Leukemia Trial (chidamide, Venetoclax Oral Tablet, Inotuzumab Ozogamicin)

Not yet recruiting
  • Acute Lymphoblastic Leukemia
  • (no location specified)
Oct 19, 2023

Obinutuzumab in Combination With Lenalidomide in Relapsed or

Recruiting
  • Follicular Lymphoma
    • Tianjin, China
      Institute of Hematology and Blood Diseases Hospital ,Chinese Aca
    Apr 27, 2023

    Mantle Cell Lymphoma, Non-hodgkin Lymphoma, Non Hodgkin Lymphoma Trial in Madison (Bendamustine, Obinutuzumab)

    Recruiting
    • Mantle Cell Lymphoma
    • +2 more
    • Madison, Wisconsin
      University of Wisconsin Carbone Cancer Center
    Sep 13, 2022

    Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma Trial run by the NCI (Obinutuzumab, Venetoclax, Magrolimab)

    Recruiting
    • Follicular Lymphoma
    • +4 more
    • Obinutuzumab
    • +2 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 20, 2023

    Chronic Lymphocytic Leukemia Trial in Portland (drug, procedure, biological, other)

    Not yet recruiting
    • Chronic Lymphocytic Leukemia
    • Portland, Oregon
      OHSU Knight Cancer Institute
    Jul 12, 2023

    Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma Trial in Boston (Obinutuzumab, Glofitamab)

    Not yet recruiting
    • Follicular Lymphoma
    • +2 more
    • Boston, Massachusetts
      Dana-Farber Cancer Institute
    Mar 13, 2023

    Obinutuzumab, Rapid Infusion, Intravenous Infusion Reaction Trial in Nanjing (intravenous rapid infusion of obinutuzumab)

    Recruiting
    • Obinutuzumab
    • +2 more
    • intravenous rapid infusion of obinutuzumab
    • Nanjing, Jiangsu, China
      Jiangsu Province Hospital
    Aug 18, 2022

    Leukemia, Lymphocytic, Chronic, B-Cell Trial in New York (Zanubrutinib Pill, Venetoclax Pill, Obinutuzumab Injection)

    Not yet recruiting
    • Leukemia, Lymphocytic, Chronic, B-Cell
    • Zanubrutinib Pill
    • +2 more
    • New York, New York
      Weill Cornell Medicine/NewYork-Presberteryian Hospital
    Dec 6, 2022

    Childhood Nephrotic Syndrome Trial (Obinutuzumab, MMF, Prednisone)

    Not yet recruiting
    • Childhood Nephrotic Syndrome
    • Obinutuzumab
    • +5 more
    • (no location specified)
    Nov 23, 2022

    Primary Membranous Nephropathy Trial in Australia (Obinutuzumab, Oral prednisolone and cyclophosphamide)

    Not yet recruiting
    • Primary Membranous Nephropathy
    • Obinutuzumab
    • Oral prednisolone and cyclophosphamide
    • Garran, Australian Capital Territory, Australia
    • +12 more
    Nov 1, 2023

    DLBCL Trial (maplirpacept (PF-07901801), Glofitamab, Obinutuzumab)

    Not yet recruiting
    • Diffuse Large B-Cell Lymphoma
    • maplirpacept (PF-07901801)
    • +2 more
    • (no location specified)
    May 30, 2023

    CCND1 Positive, Mantle Cell Lymphoma, t(11;14) Positive Trial in Atlanta, Johns Creek (Bendamustine, Obinutuzumab, Venetoclax)

    Active, not recruiting
    • CCND1 Positive
    • +2 more
    • Atlanta, Georgia
    • +2 more
    Nov 2, 2022

    Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Houston (other,

    Completed
    • Grade 3a Follicular Lymphoma
    • +9 more
    • Laboratory Biomarker Analysis
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    Jan 31, 2023

    Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Trial in Suzhou (Obinutuzumab, Zanubrutinib, Lenalidomide)

    Enrolling by invitation
    • Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
    • Obinutuzumab
    • +6 more
    • Suzhou, Jiangsu, China
      the First Affiliated Hospital of Soochow University
    Mar 22, 2023